Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control

Front‐line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control

Background Approximately 3%–5% of lung adenocarcinoma is driven by anaplastic lymphoma kinase (ALK) fusion oncogene, whose activity can be suppressed by multiple ALK inhibitors. Crizotinib and ceritinib have demonstrated superior efficacy to platinum‐based chemotherapy as front‐line treatment for pa...

Full description

Bibliographic Details
Main Authors: Shih‐Hao Huang, Allen Chung‐Cheng Huang, Chin‐Chou Wang, Wen‐Chen Chang, Chien‐Ying Liu, Stelios Pavlidis, Ho‐Wen Ko, Fu‐Tsai Chung, Ping‐Chih Hsu, Yi‐Ke Guo, Chih‐Hsi Scott Kuo, Cheng‐Ta Yang
Format: Article
Language:English
Published: Wiley 2019-12-01
Series:Thoracic Cancer
Subjects:
ALK
ceritinib
crizotinib
NSCLC
Online Access:https://doi.org/10.1111/1759-7714.13221

Internet

https://doi.org/10.1111/1759-7714.13221

Similar Items